Novartis Bags Chong Kun Dang’s HDAC6 Inhibitor In $1.3bn Deal
Potential In Cardiovascular Indications
The deal marks the biggest out-licensing agreement ever for Chong Kun Dang, with the Swiss giant poised to explore the novel small molecule in various cardiovascular indications.
